Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial
Clinical Infectious Diseases · 30.04.2026 · 82 (4) · 673-681
DOI: 10.1093/cid/ciaf241 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 13.05.2025. Verfasst von Deborah Konopnicki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department and HIV Reference Center, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium. Hauptthemen laut MEDLINE: HIV Infections, Papillomavirus Infections, Immunogenicity, Vaccine, Papillomavirus Vaccines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: King Baudouin Foundation.
Abstract (Originalsprache)
Background
The World Health Organization recommends 2 doses of human papillomavirus (HPV) vaccine for adults without human immunodeficiency virus (HIV) but 3 doses in persons with HIV. There are no immunogenicity data on the 2-dose schedule in women with HIV (WWH).
Methods
This was a prospective study comparing 2 doses (months 0 and 6) versus 3 (months 0, 2, and 6) doses of 9-valent vaccine (Gardasil 9, Merck Sharp & Dohme) in WWH (15–40 years), on antiretrovirals with HIV RNA <400 copies/mL, enrolled during 2018–2021. After an open-label phase assessing safety (n = 45 receiving 3 doses), participants were randomized between 2 or 3 doses. Primary outcome was noninferiority of 2 doses compared to 3 doses for seroconversion against all vaccine genotypes. Due to the COVID-19 pandemic, 100 WWH, instead of initially planned 120, were randomized. The trial was further amended to give 2 doses to all participants enrolled thereafter (n = 22). Results were analyzed in modified intention-to-treat (mITT) on the randomized cohort (n = 100) and per protocol on the whole cohort (n = 167).
Results
Participants’ median age was 35 years, median CD4 count was 649 cells/µL, and 16 missed the month 7 visit. In mITT, seroconversion was 97.7% for 2 doses and 97.9% for 3 doses, meeting the predefined noninferiority criteria. At month 7, antibodies titers against all vaccine genotypes were high in both groups (increase by 1.2–2.4 log10). There were no serious adverse events; participants with 3 doses experienced local reactions more frequently (82% vs 60% for 2 doses, P = .027) with more symptoms and longer duration.
Conclusions
In women with well-controlled HIV, 2 doses of 9-valent HPV vaccine is noninferior to 3 doses in terms of seroconversion and is associated with less reactogenicity. Clinical Trials Registration NCT03391921; EUDRACT 2018-000228-33; CTIS-EMA 2024-520419-42-00.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Department and HIV Reference Center, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
- Gynecology Department, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
- Laboratory of Molecular Pathology Algemeen Medisch Laboratorium, Sonic Healthcare Belgium and Belgian National Reference Laboratory for Human Papillomavirus, Antwerp, Belgium.
ORCID-Profile: Deborah Konopnicki, Davy Vanden Broeck, Nicolas Dauby
Förderung
- King Baudouin Foundation
Zitieren
APA
Konopnicki, D., Gilles, C., Manigart, Y., Barlow, P., Reschner, A., Necsoi, C., Delforge, M., Vanden Broeck, D., Dauby, N., & De Wit, S. (2026). Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial. Clinical Infectious Diseases, 82(4), 673-681. https://doi.org/10.1093/cid/ciaf241
Vancouver
Konopnicki D, Gilles C, Manigart Y, Barlow P, Reschner A, Necsoi C, et al. Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial. Clinical Infectious Diseases. 2026;82(4):673-681. doi:10.1093/cid/ciaf241
BibTeX
@article{Konopnicki2026,
author = {Konopnicki, Deborah and Gilles, Christine and Manigart, Yannick and Barlow, Patricia and Reschner, Anca and Necsoi, Coca and Delforge, Marc and Vanden Broeck, Davy and Dauby, Nicolas and De Wit, Stéphane},
title = {Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {82},
number = {4},
pages = {673--681},
doi = {10.1093/cid/ciaf241}
}
EUVIMED